Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research note issued on Saturday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Friday.

Senseonics Stock Down 0.2 %

SENS opened at $0.28 on Friday. Senseonics has a 52 week low of $0.28 and a 52 week high of $0.75. The business has a 50 day moving average price of $0.35 and a two-hundred day moving average price of $0.40. The company has a quick ratio of 2.89, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The company has a market cap of $167.77 million, a PE ratio of -2.18 and a beta of 0.79.

Hedge Funds Weigh In On Senseonics

Several institutional investors have recently added to or reduced their stakes in SENS. State Board of Administration of Florida Retirement System acquired a new position in Senseonics during the first quarter worth approximately $91,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after buying an additional 211,128 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after buying an additional 51,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares during the period. Finally, Virtu Financial LLC acquired a new position in Senseonics in the first quarter valued at $162,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.